Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies

Gheewala, Pankti A.; Peterson, Gregory M.; Zaidi, Syed Tabish Razi; Jose, Matthew; Castelino, Ronald L.

doi:10.1007/s11096-018-0603-2

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, service for chronic kidney disease was included. As a result, 62.9% of respondents suggested readiness to pay at the average amount of 10-20 USD (39.5 -79.0 PLN/SAR) [6]. Patients who participated in pharmacy health screening and who were at risk were more likely to pay for this service [3].…”

Section: Resultsmentioning

confidence: 99%

Opinions About Community Pharmacy-Based Health Screenings From Patients’ Living in Riyadh (Saudi Arabia), Poznan (Poland) and Chicago (United States of America)

Waszyk-Nowaczyk¹

2021

FARMACIA

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Opinions About Community Pharmacy-Based Health Screenings From Patients’ Living in Riyadh (Saudi Arabia), Poznan (Poland) and Chicago (United States of America)

Waszyk-Nowaczyk¹

2021

FARMACIA

View full text Add to dashboard Cite

“…This is consistent with previous evaluations of community pharmacy services designed for a range of therapeutic areas, including asthma. [32][33][34][35][36][37][38][39][40][41][42] Given that the feedback received was just as positive as PAS trials preceding the PAS, one may question the sensitivity of patient satisfaction as a measure to detect quality or value of improvements made to the health service design and delivery. Although survey respondents would not have experienced previous asthma service models, they did not proactively comment on the attributes of the service that researchers strove to improve (e.g., shorter delivery time and limited clinical elements with streamlined delivery process).…”

Section: Suggested Improvementsmentioning

confidence: 99%

Pharmacist-delivered asthma management services—what do patients think?

Serhal¹,

Saini²,

Bosnic‐Anticevich³

et al. 2022

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

Community Pharmacy-Based eGFR Screening for Early Detection of CKD in High Risk Patients

Papastergiou

Donnelly

Li³

et al. 2020

Can J Kidney Health Dis

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD) is a condition presenting with long-term slow progression of structural and/or functional damage to the kidneys. Early detection is key to preventing complications and improving outcomes. Point-of-care estimated glomerular filtration rate (eGFR) screening technology allows for detection of abnormal kidney function in the community pharmacy setting. Objective: To evaluate the effectiveness of a community pharmacist-directed point-of-care screening program and to identify the prevalence of CKD in high-risk patients. Design: Quantitative observational. Setting: Four community pharmacies in British Columbia over a 6-month period. Patients: In all, 642 participants with at least one CKD risk factor were identified and screened. Mean age was 60 years and females accounted for 55% of the study population. Measurements: Serum creatinine was measured from peripheral blood using the HeathTab® screening system (Piccolo® Renal Function Panel with the Piccolo® blood chemistry analyzer). eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Methods: Patients provided a sample of peripheral blood via a self-administered finger-prick and analytical data to assess kidney function was reported including blood urea nitrogen (BUN), serum creatinine, and electrolytes by the HealthTab® screening system. Once results were available, the pharmacist conducted a comprehensive medication review with the patient and recommended certain follow-up actions if appropriate. Results: CKD risk factor included diabetes (30%), hypertension (45%), cardiovascular disease (12%), family history of kidney disease (13%), age over 55 years (68%), and an Aboriginal, Asian, South Asian, or African ethnic background (82%). A total of 11.5% of patients had eGFR values lower than 60 mL/min (abnormal renal function) and 34% had an eGFR between 60 and 89 mL/min (minimally reduced renal function). Overall pharmacists’ actions included blood pressure check (98%), education on CKD and risk factors (89%), medication review (72%), and physician follow-up (38%). Limitations included lack of follow-up beyond the 3-month study period prevented medical confirmation of CKD and limited the ability to quantify the impact of pharmacist interventions on the clinical outcomes of patients with low eGFR. Conclusion: These results illustrate the prevalence of abnormal renal function among undiagnosed, high-risk patients in the community. Pharmacists, as the most accessible healthcare practitioners, are ideally positioned to utilize novel point-of care technologies to improve access to CKD screening, facilitate follow-up, and increase awareness around the importance of early detection.

show abstract

Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies

Abstract: Patient satisfaction with the community pharmacy-based chronic kidney disease risk assessment was high. These findings provide support for the implementation of the service within community pharmacy practice.

Cited by 3 publications

References 27 publications

Opinions About Community Pharmacy-Based Health Screenings From Patients’ Living in Riyadh (Saudi Arabia), Poznan (Poland) and Chicago (United States of America)

Opinions About Community Pharmacy-Based Health Screenings From Patients’ Living in Riyadh (Saudi Arabia), Poznan (Poland) and Chicago (United States of America)

Pharmacist-delivered asthma management services—what do patients think?

Community Pharmacy-Based eGFR Screening for Early Detection of CKD in High Risk Patients

Contact Info

Product

Resources

About